Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.39 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.39 |
| ▸ | TYR | P14679 | 2/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | BID | P55957 | 3/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.39 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.39 |
| ▸ | BAK1 | Q16611 | 2/20 | 0.39 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | EP300 | Q09472 | 1/20 | 0.39 |
| ▸ | KAT2A | Q92830 | 1/20 | 0.39 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.39 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6562306 | 0.94 | LIPG (0.48) | LIPGALOX5PTGS2ESR1ESR2 | |
| SCHEMBL28125773 | 0.92 | LIPG (0.52) | LIPGALOX5PTGS2CYSLTR2CYSLTR1 | |
| SCHEMBL6549906 | 0.92 | LIPG (0.52) | LIPGALOX5PTGS2CYSLTR2CYSLTR1 | |
| SCHEMBL27748696 | 0.92 | LIPG (0.52) | LIPGALOX5PTGS2CYSLTR2CYSLTR1 | |
| SCHEMBL11235077 | 0.92 | LIPG (0.52) | LIPGALOX5PTGS2CYSLTR2CYSLTR1 | |
| SCHEMBL9699944 | 0.92 | LIPG (0.52) | LIPGALOX5PTGS2CYSLTR2CYSLTR1 | |
| SCHEMBL3671260 | 0.92 | LIPG (0.52) | LIPGALOX5PTGS2CYSLTR2CYSLTR1 | |
| SCHEMBL7190196 | 0.92 | LIPG (0.52) | LIPGALOX5PTGS2CYSLTR2CYSLTR1 | |
| SCHEMBL5508525 | 0.92 | LIPG (0.52) | LIPGALOX5PTGS2CYSLTR2CYSLTR1 | |
| SCHEMBL11241680 | 0.92 | LIPG (0.52) | LIPGALOX5PTGS2CYSLTR2CYSLTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115386277-A | Formula and preparation process of line drawing paint suitable for sports ground | 四川乐涂智慧新材料有限公司 | 2022-11-25 | — | — | CN | claimed |
| CN-105431425-B | Compound, material for organic electroluminescent element, ink composition, organic electroluminescent element, and electronic device | 出光兴产株式会社 | 2019-10-01 | — | — | CN | claimed |
| CN-108047089-A | A kind of preparation method of 4- tert-Butyl Phthalonitriles | 郑州盖科科技有限公司 | 2018-05-18 | — | — | CN | claimed |
| US-9714207-B2 | Method for producing aromatic compound from biomass-derived acetic acid | SK INNOVATION CO., LTD. (KR) | 2017-07-25 | — | — | US | claimed |
| US-20120288752-A1 | ADDITIVE FOR OVERCHARGE PREVENTING OF SECONDARY BATTERY AND NONAQUEOUS ELECTROLYTE FOR SECONDARY BATTERY INCLUDING THE SAME | SAMSUNG CORNING PRECISION MATERIALS CO., LTD. | 2012-11-15 | — | — | US | claimed |
| EP-2523247-A1 | Additive for overcharge preventing of secondary battery and non-aqueous electrolyte for secondary battery including the same | Samsung Corning Precision Materials Co., Ltd. (KR) | 2012-11-14 | — | — | EP | claimed |
| CN-102780036-A | Additive for overcharge preventing of secondary battery and nonaqueous electrolyte including the same | SAMSUNG CORNING PREC MAT CO | 2012-11-14 | — | — | CN | claimed |
| CN-1101804-C | Pharmaceutical compound for killing cancer cells and pathogenic bacteria and prepn. method therefor | LIU QUANZHI (CN) | 2003-02-19 | — | — | CN | claimed |
| CN-1351983-A | Synthetic method for 4-terting butyl-o-xylene | INST OF YANSHAN PETROCHEMICAL (CN) | 2002-06-05 | — | — | CN | claimed |
| CN-1277956-A | Pharmaceutical compound for killing cancer cells and pathogenic bacteria and prepn. method therefor | LIU QUANZHI (CN) | 2000-12-27 | — | — | CN | claimed |
| EP-0290442-A4 | PHARMACOLOGICALLY ACTIVE COMPOUNDS AND MIXTURES THEREOF, ORGANIC COMPOSITIONS AND METAL SALTS. | CHEMEX PHARMACEUTICALS INC (US) | 1990-07-03 | — | — | EP | claimed |
| EP-0290442-A1 | PHARMACOLOGICALLY ACTIVE COMPOUNDS AND MIXTURES THEREOF, ORGANIC COMPOSITIONS AND METAL SALTS | CHEMEX PHARMACEUTICALS, INC. (US) | 1988-11-17 | — | — | EP | claimed |
| WO-1988003805-A1 | PHARMACOLOGICALLY ACTIVE COMPOUNDS AND MIXTURES THEREOF, ORGANIC COMPOSITIONS AND METAL SALTS | CHEMEX PHARMACEUTICALS, INC. (US) | 1988-06-02 | — | — | WO | claimed |
| US-20260062769-A1 | METHOD OF LEACHING NICKEL FROM OXIDIZED ORE, METHOD OF MANUFACTURING NICKEL SULFATE, AND NICKEL-LEACHING AGENT | PRIME PLANET ENERGY & SOLUTIONS INC (JP) | 2026-03-05 | — | — | US | disclosed |
| US-20260062315-A1 | METHOD OF LEACHING NICKEL FROM OXIDIZED ORE, METHOD OF MANUFACTURING NICKEL SULFATE, AND NICKEL-LEACHING AGENT | PRIME PLANET ENERGY & SOLUTIONS INC (JP) | 2026-03-05 | — | — | US | disclosed |
| CN-117069587-A | Nitrobenzene crystal and application thereof in pharmaceutical composition | 齐金 | 2023-11-17 | — | — | CN | disclosed |
| EP-0226918-A1 | Process for the catalytic oxidation of 4-tertiary-butyl-o-xylene | BASF Aktiengesellschaft (DE) | 1987-07-01 | — | — | EP | disclosed |
| US-4165343-A | Dehydration of tertiary butyl alcohol | CITIES SERVICE CONMPANY (US) | 1979-08-21 | — | — | US | disclosed |
| US-4048212-A | Process for the manufacture of 1,4-dicyanonaphthalenes | CIBA-GEIGY CORPORATION (US) | 1977-09-13 | — | — | US | disclosed |
| US-4011261-A | PROCESS FOR THE MANUFACTURE OF 1,4-DISUBSTITUTED BICYCLIC OR TRICYCLIC COMPOUNDS AND NEW 1,4-DISUBSTITUTED BICYCLIC COMPOUNDS | CIBA-GEIGY CORPORATION (US) | 1977-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062769-A1 | METHOD OF LEACHING NICKEL FROM OXIDIZED ORE, METHOD OF MANUFACTURING NICKEL SULFATE, AND NICKEL-LEACHING AGENT | HAO2, LIPA, YAP1 | LIPG 1249/4885ALOX5 38/4885PTGS2 2486/4885 |
| US-20260062315-A1 | METHOD OF LEACHING NICKEL FROM OXIDIZED ORE, METHOD OF MANUFACTURING NICKEL SULFATE, AND NICKEL-LEACHING AGENT | SLC9A2, HAO2, SLC9A3 | LIPG 1403/4885ALOX5 140/4885PTGS2 1737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.